# GSK plc 14.7% potential upside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/gsk-plc-14-7-potential-upside-indicated-by-deutsche/4121146500
- Published: 2024-03-07T14:20:27+00:00
- Author: Charlotte Edwards

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
with ticker ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
now has a potential upside of 14.7% according to Deutsche.
Deutsche set a target
price of 1,950 GBX for the company, which when compared to the GSK plc share price
of 1,700 GBX at opening today (07/03/2024) indicates a potential upside of 14.7%.
Trading has ranged between 1,303 (52 week low) and 1,726 (52 week high) with an 
average of 7,840,390 shares exchanging hands daily. The market capitalisation at
the time of writing is £70,722,394,884.GSK plc is a global biopharma company. The
Company’s segments include Commercial Operations and Research and Development. It
develops cancer medicines for patients, including ovarian cancer, endometrial cancer,
and multiple myeloma. It has developed monoclonal antibodies to help treat different
diseases. Its product areas include vaccines, specialty medicines, and general medicine.
It is also focused on addressing the unmet treatment needs of patients with respiratory
and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines
that help to protect people from a range of diseases and infections, including meningitis,
shingles and flu, among others. Its specialty medicines include medicines for immune-
mediated conditions. Its specialty medicines are also engaged in developing medicines
for respiratory disease and HIV. Its general medicines include inhaled medicines
for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines
for skin diseases.

Share on:
